Abstract
In recent years new oral anticoagulants have been evaluated in the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, atrial fibrillation to prevent ischemic stroke and in the treatment of acute VTE. While two oral anticoagulants, dabigatran and rivaroxaban, have become available for the prevention of VTE in orthopaedic surgery, other indications still are under evaluation or await approval. There are also areas where these novel drugs have not yet been evaluated. These include patients with acute VTE and cancer, pregnant patients with acute VTE and patient with either rheumatic heart valve disease or artificial heart valves. Finally, in acute care settings, where anticoagulant reversibility is critical, such as during and after coronary artery bypass surgery or acute PCI setting in patients with high bleeding risk, novel intravenous anticoagulant drugs with either short half life or specific antidotes may have added value. This article will focus on these unresolved issues.
Keywords: Thrombosis, new anticoagulants, pregnancy, heart valves, cancer, Anticoagulants, venous thromboembolism, knee arthroplasty, atrial fibrillation, ischemic stroke, dabigatran, rivaroxaban, orthopaedic surgery, rheumatic heart valve disease, artificial heart valves, acute PCI setting, intravenous anticoagulant drugs, coronary artery bypass, tumour, Low-molecular-weight heparin, fondaparinux, hromboprophylaxis, renal dysfunction, creatinine clearance, apixaban, hepatotoxic, hepatic metastases, chemotherapy, Vitamin K antagonists, anti-factor Xa, heparin induced thrombocytopenia, Otamixaban, Eptifibatide in Non-ST, Elevation Acute Coronary Syndrome, myocardial infarction, RB006, antithrombotic prophylaxis, hypercoagulable state
Current Pharmaceutical Design
Title: Further Issues with New Oral Anticoagulants
Volume: 16 Issue: 31
Author(s): M. V. Huisman
Affiliation:
Keywords: Thrombosis, new anticoagulants, pregnancy, heart valves, cancer, Anticoagulants, venous thromboembolism, knee arthroplasty, atrial fibrillation, ischemic stroke, dabigatran, rivaroxaban, orthopaedic surgery, rheumatic heart valve disease, artificial heart valves, acute PCI setting, intravenous anticoagulant drugs, coronary artery bypass, tumour, Low-molecular-weight heparin, fondaparinux, hromboprophylaxis, renal dysfunction, creatinine clearance, apixaban, hepatotoxic, hepatic metastases, chemotherapy, Vitamin K antagonists, anti-factor Xa, heparin induced thrombocytopenia, Otamixaban, Eptifibatide in Non-ST, Elevation Acute Coronary Syndrome, myocardial infarction, RB006, antithrombotic prophylaxis, hypercoagulable state
Abstract: In recent years new oral anticoagulants have been evaluated in the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, atrial fibrillation to prevent ischemic stroke and in the treatment of acute VTE. While two oral anticoagulants, dabigatran and rivaroxaban, have become available for the prevention of VTE in orthopaedic surgery, other indications still are under evaluation or await approval. There are also areas where these novel drugs have not yet been evaluated. These include patients with acute VTE and cancer, pregnant patients with acute VTE and patient with either rheumatic heart valve disease or artificial heart valves. Finally, in acute care settings, where anticoagulant reversibility is critical, such as during and after coronary artery bypass surgery or acute PCI setting in patients with high bleeding risk, novel intravenous anticoagulant drugs with either short half life or specific antidotes may have added value. This article will focus on these unresolved issues.
Export Options
About this article
Cite this article as:
V. Huisman M., Further Issues with New Oral Anticoagulants, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563356
DOI https://dx.doi.org/10.2174/138161210793563356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomaterials and Fabrication to Optimise Scaffold Properties for Musculoskeletal Tissue Engineering
Current Stem Cell Research & Therapy Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Neuronal Regulation of Aortic Valve Cusps
Current Vascular Pharmacology ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology In Situ Oxidative Stress and Atrial Cell Deaths in Patients with Valve Disease
Cardiovascular & Hematological Disorders-Drug Targets Balancing the Risks of Thrombosis and Bleeding Following Transcatheter Aortic Valve Implantation: Current State-of-Evidence
Current Pharmaceutical Design Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Impact of Pre-existing Kidney Dysfunction on Outcomes Following Transcatheter Aortic Valve Replacement
Current Cardiology Reviews The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Artificial Organs: A New Option for Treating Osteoarthritis
Current Drug Delivery Designing Recombinant Collagens for Biomedical Applications
Current Tissue Engineering (Discontinued) Perioperative Considerations in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Training Standards and Recommendations for Intervention on Chronic Total Occlusions
Current Cardiology Reviews Percutaneous Pulmonary Valve Implantation: Current Status and Future Perspectives
Current Cardiology Reviews Structure-Activity Relationships of Low Molecular Weight Heparins Expose to the Risk of Achieving Inappropriate Targets in Patients with Renal Failure
Current Medicinal Chemistry